U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07308379) titled 'Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer' on Dec. 15.
Brief Summary: This is a prospective, observational, multi-center, real-world study evaluating the effectiveness and safety of Toripalimab (a PD-1 inhibitor) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The primary objective is to assess real-world progression-free survival (rwPFS). Secondary objectives include evaluating real-world objective response rate (rwORR), disease control rate (rwDCR), overall survival (rwOS), and safety. Approximately 1200 patients from multiple centers in China will be enro...